| Ytd | 45.15% | |
| 1y | 86.76% |
| Open | 31.43 | Prev Close | 30.90 | Low | 31.04 | High | 32.35 | Mkt Cap | 926.54M |
| Vol | 172.83K | Avg Vol | 230.57K | EPS | -1.73 | P/E | -18.68 | Forward P/E | N/A |
| Beta | N/A | Short Ratio | N/A | Inst. Own | N/A | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 05-15 | 50-d Avg | 30.30 | 200-d Avg | 23.93 | 1yr Est | 0.00 |
LBRX News
BMO Capital analyst Malcolm Hoffman initiates coverage on LB Pharmaceuticals (NASDAQ:LBRX) with a
Wolfe Research analyst Rudy Li initiates coverage on LB Pharmaceuticals (NASDAQ:LBRX) with a Outp
LB Pharmaceuticals (NASDAQ:LBRX) reported quarterly losses of $(0.67) per share which beat the analy
Top Wall Street analysts changed outlook on top names. See analyst rating changes, including upgrade
HC Wainwright & Co. analyst Raghuram Selvaraju initiates coverage on LB Pharmaceuticals (NASD
Craig-Hallum analyst Adam Vogel initiates coverage on LB Pharmaceuticals (NASDAQ:LBRX) with a Buy
LB Pharmaceuticals Inc ("LB Pharmaceuticals" or the "Company") (NASDAQ:LBRX), a late
Stifel analyst Paul Matteis maintains LB Pharmaceuticals (NASDAQ:LBRX) with a Buy and raises the
LB Pharmaceuticals (NASDAQ:LBRX) reported quarterly losses of $(0.45) per share which beat the analy
LB Pharmaceuticals Inc ("LB Pharmaceuticals" or the "Company") (Nasdaq: LBRX), a lat